LAMICTAL ODT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LAMICTAL ODT (LAMICTAL ODT).
Lamotrigine is a triazine derivate that stabilizes presynaptic neuronal membranes by blocking voltage-sensitive sodium channels, thereby inhibiting the release of excitatory neurotransmitters (e.g., glutamate). This suppresses neuronal hyperexcitability and prevents seizure spread.
| Metabolism | Primarily metabolized by UGT1A4 (major pathway) and UGT2B7 (minor pathway), producing an inactive N-glucuronide conjugate. Does not inhibit or induce CYP450 enzymes. |
| Excretion | Primarily hepatic metabolism (glucuronidation by UGT1A4); 70-90% excreted renally as metabolites, 2% unchanged; 2-10% fecal |
| Half-life | Terminal elimination half-life: 25-39 hours (single dose), 12-22 hours (with enzyme inducers), 30-70 hours (with valproate); clinically relevant for dosing titration to avoid Stevens-Johnson syndrome |
| Protein binding | 55% bound to plasma proteins (albumin) |
| Volume of Distribution | 0.9-1.3 L/kg; distributes extensively into tissues; higher in CNS than plasma |
| Bioavailability | 98% (oral, Lamictal ODT); no significant first-pass metabolism |
| Onset of Action | Oral: 1-4 hours (chewable/dispersible tablet absorbed rapidly); clinical effect onset: days to weeks for mood stabilization |
| Duration of Action | 24-36 hours after single dose; steady-state achieved in 3-5 days (monotherapy) or longer with interacting drugs |
Initial 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then increase by 50 mg daily every 1-2 weeks; maintenance 100-200 mg twice daily (200-400 mg/day). For monotherapy or as add-on in epilepsy and bipolar disorder.
| Dosage form | TABLET, ORALLY DISINTEGRATING |
| Renal impairment | For CrCl <10 mL/min: avoid use. For CrCl 10-30 mL/min: reduce initial dose by 50% and titrate slowly. For CrCl 30-50 mL/min: use 50% of usual starting dose. No specific recommendation for dialysis; avoid if possible. |
| Liver impairment | Child-Pugh Class A: 50% reduction in initial dose and slower titration. Child-Pugh Class B: 75% reduction in initial dose and slower titration. Child-Pugh Class C: contraindicated. If used, extreme caution with 90% dose reduction and ultra-slow titration. |
| Pediatric use | Epilepsy (age 2-12): weeks 1-2: 0.15 mg/kg/day once daily; weeks 3-4: 0.3 mg/kg/day once daily; then increase by 0.3 mg/kg/day every 1-2 weeks; maintenance 1-5 mg/kg/day twice daily (max 400 mg/day). For bipolar disorder (age 13-17): same as adult dosing. |
| Geriatric use | Start at 25 mg every other day for 2 weeks, then 25 mg once daily for 2 weeks, then 50 mg once daily, then increase by 25-50 mg/day every 1-2 weeks; lower maintenance doses often sufficient. Monitor for renal function, dizziness, and ataxia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LAMICTAL ODT (LAMICTAL ODT).
| Breastfeeding | Lamotrigine is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.6. Infant serum levels can reach 10-50% of maternal levels. Monitoring for adverse effects such as apnea, drowsiness, and poor feeding is recommended. The benefits of breastfeeding generally outweigh risks, but caution is advised, especially in premature or ill infants. |
| Teratogenic Risk | Lamotrigine (LAMICTAL ODT) is associated with an increased risk of oral clefts (cleft lip/palate) following first-trimester exposure, with an absolute risk of approximately 0.3-0.9% compared to 0.1% in the general population. There is also a possible risk of other congenital malformations. Later trimester exposure may be associated with neonatal withdrawal or toxicity, including jitteriness, hypotonia, and respiratory depression. |
■ FDA Black Box Warning
Life-threatening serious rashes including Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported. Discontinue at first sign of rash unless clearly not drug-related. Risk is increased with coadministration of valproate, exceeding recommended initial dose or dose escalation rate, or concurrent use of other antiepileptics known to cause rash.
| Serious Effects |
["Hypersensitivity to lamotrigine or any component of the formulation"]
| Precautions | ["Risk of serious rashes (including SJS, TEN, DRESS) – must follow titration schedule","Hypersensitivity reactions (fever, lymphadenopathy, eosinophilia) – may occur without rash","Suicidal thoughts and behavior – monitor for emergence or worsening of depression","Aseptic meningitis – symptoms include headache, fever, stiff neck; discontinue","Blood dyscrasias (e.g., neutropenia, thrombocytopenia) – rare","Withdrawal seizures – avoid abrupt discontinuation","Hepatic failure – rare, monitor in patients with hepatic impairment","Renal impairment – reduced clearance, use lower doses"] |
Loading safety data…
| Fetal Monitoring | Maternal monitoring should include serum lamotrigine levels at least every 4 weeks during pregnancy and postpartum, as levels can decrease by up to 50-70% in pregnancy due to increased clearance. Fetal monitoring includes ultrasound for detection of oral clefts (cleft lip/palate) at 18-20 weeks gestation. Newborns should be observed for signs of neonatal withdrawal or toxicity (e.g., jitteriness, hypotonia, respiratory depression). |
| Fertility Effects | Lamotrigine does not have known adverse effects on fertility in humans. Studies in animals have shown no impairment of fertility at clinically relevant doses. No specific human data indicate negative impacts on female or male reproductive function. |